Phoenix Asia Holdings Limited

Sources: FY2023–FY2025 from audited statements in the 20-F and prospectus, as tabulated by TipRanks. FY2026 from the 20-F FY2026 (revenue) and summaries of it (gross profit, margin, net loss: Panabee), plus Yahoo Finance trailing data (EPS, cash). FY2022 predates the company's audited disclosure window and is not publicly disclosed. All figures are in USD millions unless labelled.

Income statement

Notes: FY2025 pre-tax income is derived from a 17.6% pre-tax margin on revenue of 7.37 (dividend.watch). FY2025 effective tax rate was 20.9%. EPS for FY2023–FY2025 is from roic.ai; the FY2026 EPS of −0.06 is Yahoo Finance's trailing diluted EPS. FY2026 operating income and EBITDA are not reported in the sources retrieved. The net loss implies a negative operating result after G&A, which listing costs probably increased. TradingView shows a negative EBITDA, but its basis is unclear, so it is not used.

Margins and growth

Revenue CAGR: FY2023→FY2025 was about 81.8% a year. FY2023→FY2026 was about 47.8% a year. Both are analyst calculations from the table above.

Balance sheet

Notes: FY2026 cash of 1.29 is Yahoo Finance's most-recent-quarter figure. FY2026 BVPS of 0.29 is from roic.ai, which implies equity of about USD6.3 M on 21.6 M shares. That is lower than a simple roll-forward (3.11 + about 5.76 net IPO proceeds − 1.2 loss ≈ 7.7), so the gap is unexplained. Short-term and long-term debt splits are not publicly disclosed in the sources retrieved; the debt appears to be lease or small borrowings. Working capital is not publicly disclosed. A long-service-payment provision of USD10,781 at 31 Mar 2026 (USD6,625 a year earlier) sits in non-current liabilities (20-F FY2026). Goodwill and intangibles are nil, as no acquisitions have closed.

Cash flow

Notes: The FY2026 free cash flow of −4.02 is Yahoo Finance's trailing "levered free cash flow", an aggregator estimate not reconciled to the 20-F. It suggests a large working-capital outflow, likely contract assets and receivables tied to disputed variation orders, during the year the IPO cash came in. FY2023–FY2025 capex is derived from the gap between operating cash flow and free cash flow.

Ratios

Sources and method: FY2025 ROE, ROA and interest coverage per dividend.watch. FY2026 ROE and ROA are Yahoo Finance trailing figures. FY2024 ROE and ROA, and the asset turnover figures, are analyst calculations on average balances. Debt/equity is calculated from the table above. ROIC, current ratio and cash conversion cycle are not publicly disclosed in the sources retrieved.

Commentary on trends, inflections and drivers

FY2023–FY2024: rapid scaling. Revenue rose about 2.6× to USD5.76 M as Winfield won larger contracts, including the riding-school redevelopment and the public trunk-road job. Gross margin held at about 25–26%, and operating leverage lifted operating margin to 21.4%. Cash conversion improved from negative operating cash flow in FY2023 to USD0.54 M. That pattern is typical of a small contractor gaining scale while keeping overhead lean.

FY2025: peak profitability, pre-IPO. Revenue grew 28% to USD7.37 M and gross margin peaked at 29.5%. However, operating margin fell to 17.6% and net income fell slightly to USD1.03 M because G&A rose, probably including pre-IPO professional fees. Operating cash flow of USD1.18 M and year-end cash of USD2.38 M left the company with a net-cash balance sheet and almost no debt.

FY2026: the inflection. The first post-IPO year was the worst in the disclosure window. Revenue was roughly flat (−2.3% to about USD7.2 M), but gross margin collapsed from 29.5% to 4.6% and gross profit fell about 85% to about USD0.3 M. Management explained the H1 decline: completed projects were not fully replaced, and customer-ordered variation works were carried out while their pricing was still being negotiated (31 Mar 2026 release). The implied H2 shows the problem worsened, with a gross loss of about USD0.4 M. Add public-company costs (listing, D&O insurance, board fees, US audit and legal) and the company posted a net loss of about USD1.2 M against a USD1.03 M profit a year earlier. Trailing free cash flow of about −USD4.0 M (Yahoo) means most of the IPO money appears to have been absorbed by working capital or other uses. Cash fell to about USD1.29 M. The four disclosed material weaknesses, including limited precision in reviewing the CECL (expected credit loss) allowance, raise further doubts about the quality of the receivable and contract-asset balances.

Forward implications. Unless the disputed variation orders are settled in Winfield's favour, which would bring a margin recovery, the standalone construction business looks loss-making at its current scale and cost base. The USD20 M convertible note issued in May 2026 for advisory services, after the FY2026 balance-sheet date, could produce a very large non-cash expense or liability in FY2027 relative to the company's equity. Its accounting treatment has not yet been disclosed.

Management guidance

None. Phoenix Asia issues no quantitative guidance. Its only forward-looking strategic statement is the intent to become a pharmaceutical holding company after acquiring ACEA Pharma.

Consensus expectations

None. There is no sell-side coverage.

Bull case

1. Transformational re-rating. If the ACEA acquisition closes, the company becomes a USD1 B-plus agreed-value clinical-stage pharma platform with oncology, autoimmune and COVID-19 programmes and Greater China ZTlido rights. The construction business would become a rounding error, and the stock would be valued on pipeline potential.

2. Construction margin recovery. The FY2026 margin collapse was largely caused by variation orders still under negotiation. Favourable settlements could restore gross margins towards the 25–30% range of FY2023–FY2025, and some cost recovery could flow straight to profit.

3. Clean balance sheet and supportive controller. Bank debt is negligible. Because the controller holds about 74.5%, interests are aligned on deal completion, and the zero-coupon note structure means no cash interest burden.

Bear case

1. Deal risk with weak counterparties. Closing has slipped past the Q2 2026 target. Scilex is in a liquidity crisis (USD0.6 M cash, about USD93.5 M debt). The USD1 B agreed value is about 26× ACEA's 2021 implied value, with no disclosed target financials. Nasdaq may treat the deal as a change of control that requires a fresh listing application.

2. Deteriorating core business. FY2026 brought a 4.6% gross margin, a net loss of about USD1.2 M, an implied H2 gross loss, 97% customer concentration, falling cash and ineffective internal controls. Standalone, the construction business does not support even a small fraction of the current market cap.

3. Governance and dilution. A USD20 M convertible note was given to the controlling shareholder for advisory services, about three times FY2025 book equity. Existing public holders would be diluted to about 1.3% (IPO float) and all non-ACEA holders to about 18% of the combined company. The agreed USD10 per-share deal price is well below the current trading price, so the market price is not anchored to the deal.

Catalysts and monitorables (next 12 months)

Analyst verdict

Phoenix Asia Holdings should not be analysed as the construction company it currently reports as. It should be analysed as a listing vehicle with an option on a highly uncertain pharmaceutical transaction. The underlying business, Winfield Engineering, is a legitimate but tiny Hong Kong foundation subcontractor. It grew quickly from FY2023 to FY2025, then in its first year as a public company its gross margin fell from 29.5% to 4.6%, it moved from a USD1.0 million profit to a USD1.2 million loss, and it reported ineffective internal controls. With 97% of revenue from five customers and no disclosed backlog, its standalone fair value is a small fraction of the roughly USD378 million market capitalisation, perhaps in the low tens of millions at best.

The equity value therefore rests on the ACEA Pharma acquisition. The structure is unusual: a USD1 billion agreed value for a target bought for about USD38 million five years ago, payment entirely in newly issued shares at USD10 (well below the trading price), a seller parent in acute financial distress, and a USD20 million convertible note awarded to the controlling shareholder for advisory work. The deal has missed its own Q2 2026 closing target without a public explanation located in this research. Even if it closes, current minority holders would own a very small slice of a clinical-stage company whose individual assets have not been named.

The share price, which has ranged from USD2.31 to USD133.12 and is now about USD17.51, is driven by a free float of about 1.6 million shares, not by fundamentals. For institutional investors, the key considerations are governance, liquidity and binary deal risk, not construction-cycle exposure. Verdict: speculative, event-driven situation with very high risk; fundamental support is limited until audited ACEA financials, a fairness opinion and a confirmed closing are disclosed. Monitoring priorities are Form 6-K filings on the deal's status, the accounting for the USD20 million note, and any Nasdaq listing determination.

The author is not a financial advisor. Figures marked as derived or from aggregators should be checked against the primary SEC filings (EDGAR CIK 0002035709) before use.